Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs) - PubMed (original) (raw)

Review

Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs)

Joan S Lewis-Wambi et al. Breast Dis. 2005.

Abstract

Endocrine therapy that targets the estrogen receptor (ER) is a standard of care for the treatment of postmenopausal women with ER-positive breast cancer. The selective ER modulator (SERM) tamoxifen has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of ER-positive disease. Tamoxifen blocks the action of estrogen by binding to the ER, and possesses both ER-agonist and antagonist properties. Unfortunately, long-term use of tamoxifen is associated with several important concerns including an increased risk of endometrial cancer and thromboembolic complications. In addition, many patients who initially respond to tamoxifen eventually relapse with resistant disease. New treatment approaches are therefore required. A number of alternative SERMs have been tested as substitutes for tamoxifen. These include; toremifene, droloxifene, idoxifene, and keoxifene. Unfortunately, the SERMs have not proved to be more effective than tamoxifen for the treatment of advanced breast cancer and have shown a high level of cross-resistance with tamoxifen. The subsequent development of the aromatase inhibitors (AIs) is an important therapeutic advance by creating a "no estrogen" environment. Another approach is the development of pure antiestrogens. Fulvestrant is a novel ER antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects. It produces high response rates compared with other SERMs and is not cross-resistant to tamoxifen or aromatase inhibitors and is equally as effective as the AI anastrozole in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant tamoxifen therapy. This review article discusses the significant and continuing value of SERMs for the treatment of postmenopausal ER-positive breast cancer.

PubMed Disclaimer

Cited by

Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.
Dauchy RT, Xiang S, Mao L, Brimer S, Wren MA, Yuan L, Anbalagan M, Hauch A, Frasch T, Rowan BG, Blask DE, Hill SM. Dauchy RT, et al. Cancer Res. 2014 Aug 1;74(15):4099-110. doi: 10.1158/0008-5472.CAN-13-3156. Cancer Res. 2014. PMID: 25062775 Free PMC article.
Regulation of hormonal therapy resistance by cell cycle machinery.
Nair BC, Vadlamudi RK. Nair BC, et al. Gene Ther Mol Biol. 2008 Jan 1;12:395. Gene Ther Mol Biol. 2008. PMID: 20148177 Free PMC article.
Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target.
Caciolla J, Bisi A, Belluti F, Rampa A, Gobbi S. Caciolla J, et al. Molecules. 2020 Nov 16;25(22):5351. doi: 10.3390/molecules25225351. Molecules. 2020. PMID: 33207783 Free PMC article. Review.
In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K, Munuganti RS, Leblanc E, Lin YL, Leung E, Lallous N, Butler M, Cherkasov A, Rennie PS. Singh K, et al. Breast Cancer Res. 2015 Feb 25;17(1):27. doi: 10.1186/s13058-015-0529-8. Breast Cancer Res. 2015. PMID: 25848700 Free PMC article.
Chemoprevention of Rat Mammary Carcinogenesis by Apiaceae Spices.
Aqil F, Jeyabalan J, Munagala R, Ravoori S, Vadhanam MV, Schultz DJ, Gupta RC. Aqil F, et al. Int J Mol Sci. 2017 Feb 16;18(2):425. doi: 10.3390/ijms18020425. Int J Mol Sci. 2017. PMID: 28212313 Free PMC article.

Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs) - PubMed (original) (raw)